Why has the Pro Medicus share price surged 32% in a month?

Recent contract wins are improving the company's earnings outlook.

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Pro Medicus share price has been rising over the past month
  • The company has recently won contract renewals at a higher fee per transaction
  • The business has a very high EBIT margin

The Pro Medicus Limited (ASX: PME) share price has been surging higher in recent weeks. It closed 5.7% higher at $51.17 on Thursday and is now up 32% in a month.

This year has been a volatile one for the ASX healthcare share. It climbed above $66 earlier in the year before falling below $38 in mid-June. But it has been going upwards since then.

The company may have partly gone up as part of a broader recovery along with many other ASX growth shares. For example, the Xero Limited (ASX: XRO) share price has risen 18% over the past month and the REA Group Limited (ASX: REA) share price has soared by around 23%. The S&P/ASX 200 Index (ASX: XJO) is up by more than 4% over the same timeframe.

But, the rise that Pro Medicus has experienced only recovers some of the lost ground — the current price represents a fall of around 19% this year to date.

Contract wins

Pro Medicus announced in mid-June that its Visage Imaging business had signed two contract renewals with a combined minimum value of $47 million. These two were Sutter Health, which renewed for seven years, and Wellspan Health, which renewed for five.

The contract renewals are transaction-based with committed minimums with potential upside.

For me, and perhaps investors, a key element from the update was that the renewals were negotiated at an increased fee per transaction compared to the original contracts.

Pro Medicus CEO Dr Sam Hupert explained why this update was so positive:

The industry norm for renewals is for short extensions to the original contract at the same or lower price. The fact that our clients have renewed for a full or longer contract term at an increased price supports our belief that the Visage solution delivers unparalleled value both in terms of financial and clinical ROI (return on investment).

Whilst it is still early days, our renewal success rate sends a positive message to the market and helps build on the network effect that we have been experiencing.

Extremely profitably

Pro Medicus has one of the highest earnings before interest and tax (EBIT) margins on the ASX. In the FY22 half-year result, the EBIT margin was 65%. This helped net profit after tax (NPAT) grow by 52.7% to $20.7 million, which then funded a 42.9% rise of the interim dividend to 10 cents per share.

Any new revenue that the company generates is being turned into profit at a high rate. Therefore, contract wins and contract renewals (with a higher fee per transaction) can help Pro Medicus' profit. Rising profit can be an important factor for pushing the Pro Medicus share price higher.

Pro Medicus share snapshot

Despite its recent gains, the Pro Medicus share price remains 12% over the past 12 months.

At the current share price, the company has a market capitalisation of $5 billion, according to the ASX.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »